Schizophrenia is a global condition with an incidence of 15.2 per 100,000 people per year worldwide. Across the page, you’ll see how risk and outcomes connect—from genetics and family history to exposures like cannabis use disorder and prenatal famine. We also map symptom patterns, treatment response (including what makes some cases treatment-resistant), and real-world impacts such as disability, suicide risk, and reduced life expectancy.
Key Takeaways
- Genetic risk variants explain 24% of schizophrenia liability, with polygenic scores predicting 7% variance, per PGC GWAS
- Family risk: first-degree relatives have 10% risk versus 1% general population, heritability 80%, twin studies
- Cannabis use disorder doubles schizophrenia risk, odds ratio 2.09, dose-dependent per Copenhagen study
- Worldwide, approximately 24 million people, or 1 in 300 people (0.32%), develop schizophrenia, representing a significant global mental health burden as of 2019 data
- In the United States, schizophrenia affects about 3.5 million adults, with a lifetime prevalence of 1.1% among adults aged 18 and older based on the National Comorbidity Survey Replication
- The incidence rate of schizophrenia is estimated at 15.2 per 100,000 individuals per year globally, with higher rates in urban areas compared to rural settings according to a 2012 meta-analysis
- 20-30% of first-episode patients achieve full recovery within 5 years without relapse, per long-term studies
- Suicide rate in schizophrenia is 5%, 20 times general population, 80% attempt lifetime
- 50% of patients experience significant disability, with 10-15% requiring lifelong institutionalization
- Positive symptoms like hallucinations occur in 70-80% of schizophrenia patients at some point, per DSM-5 field trials
- Auditory hallucinations are reported by 60-90% of schizophrenia patients, most commonly voices commenting or conversing, from meta-analyses
- Delusions of persecution affect 50-60% of patients, while grandiose delusions occur in 25-30%, per clinical phenomenology studies
- 65% of schizophrenia patients respond to antipsychotics within 6 weeks, but 30% are treatment-resistant, per CATIE trial phase 1
- Clozapine achieves 30-50% response in treatment-resistant cases versus 4% placebo, CATIE phase 2
- Cognitive behavioral therapy for psychosis (CBTp) reduces delusions by 15-20% on PANSS, meta-analysis 34 RCTs
Schizophrenia risk blends strong genetics with modifiable factors like cannabis, causing major global disability and early onset.
Related reading
01 · Category
Etiology And Risk Factors19 stats
01
Genetic risk variants explain 24% of schizophrenia liability, with polygenic scores predicting 7% variance, per PGC GWAS
02
Family risk: first-degree relatives have 10% risk versus 1% general population, heritability 80%, twin studies
03
Cannabis use disorder doubles schizophrenia risk, odds ratio 2.09, dose-dependent per Copenhagen study
04
Prenatal famine exposure increases risk 1.7-fold, as in Dutch Hunger Winter cohort of 400,000
05
Advanced paternal age (>45) raises risk 3.8-fold due to de novo mutations, meta-analysis of 5M births
06
Childhood trauma (physical abuse) OR 2.78 for psychosis, dose-response in 38 studies meta-analysis
07
Dopamine D2 receptor gene variants contribute 3-5% risk, interacting with environment
08
Obstetric complications like hypoxia OR 1.5-2.0, in 17 cohorts totaling 52K cases
09
Urban birth OR 2.5 for schizophrenia, mediated 30% by social causation, Swedish registry
10
DISC1 gene disruptions confer 40-70% risk in Scottish families, neurodevelopmental effects
11
Maternal influenza during pregnancy OR 1.5 for offspring schizophrenia, Danish cohort 1.2M
12
Autoimmune disorders in family increase risk 1.5-fold, shared genetics/inflammation
13
Vitamin D deficiency in utero OR 1.4, Australian case-control study 271 cases
14
COMT Val158Met polymorphism moderates stress-psychosis link, OR 2.0 under adversity
15
Migration status OR 2.7 overall, highest 4.6 for second-generation migrants, meta-analysis
16
Lead exposure childhood HR 1.4 per SD increase, New England cohort 571 cases
17
NRG1 gene variants associated with 1.2-1.5 OR, white matter abnormalities
18
Head injury before age 18 OR 1.6, meta-analysis 11 studies
19
C4 gene copy number variation mediates synaptic pruning, explaining 0.66% risk
Interpretation
Etiology And Risk Factors Interpretation
Across the etiology and risk factors for schizophrenia, inherited liability and early-life exposures jointly stand out as major drivers, with first-degree relatives showing a 10% risk versus 1% in the general population and cannabis use disorder roughly doubling risk with an odds ratio of 2.09, while prenatal famine exposure increases risk by 1.7-fold and advanced paternal age over 45 raises it 3.8-fold.
02 · Category
Prevalence And Epidemiology20 stats
01
Worldwide, approximately 24 million people, or 1 in 300 people (0.32%), develop schizophrenia, representing a significant global mental health burden as of 2019 data
02
In the United States, schizophrenia affects about 3.5 million adults, with a lifetime prevalence of 1.1% among adults aged 18 and older based on the National Comorbidity Survey Replication
03
The incidence rate of schizophrenia is estimated at 15.2 per 100,000 individuals per year globally, with higher rates in urban areas compared to rural settings according to a 2012 meta-analysis
04
Males have a higher incidence of schizophrenia than females, with a male-to-female ratio of 1.4:1, peaking in late adolescence for men and late 20s for women per epidemiological studies
05
In Europe, the pooled prevalence of schizophrenia is 5.0 per 1,000 persons, varying from 3.0 to 7.2 per 1,000 across countries as per the EUFEST study data
06
Schizophrenia spectrum disorders have a point prevalence of 4.6 per 1,000 in high-income countries versus 3.7 per 1,000 in low- and middle-income countries, from a 2016 systematic review
07
Among African Americans in the US, the prevalence of schizophrenia is 2.4 times higher than in White Americans, adjusted for age and sex, per NESARC data
08
The age-standardized incidence rate of schizophrenia decreased by 13.4% globally from 1990 to 2019, according to the Global Burden of Disease Study
09
In Australia, lifetime prevalence of psychotic disorders including schizophrenia is 1.5% for men and 1.9% for women, from the 2020-2022 National Study of Mental Health
10
Urbanicity increases schizophrenia risk by 2-3 fold, with odds ratios up to 2.37 in a Danish cohort study of over 2 million people
11
Migrant groups show 2-5 times higher incidence of schizophrenia, particularly from certain regions, per a 2008 meta-analysis of 12 countries
12
In China, the prevalence of schizophrenia is 4.8 per 1,000, higher in males (5.5) than females (4.1), from a 2018 national survey
13
The global prevalence of schizophrenia in children under 18 is 1 in 40,000, increasing sharply after puberty per child psychiatry reviews
14
In the UK, diagnosed schizophrenia affects 1 in 100 adults, with Black Caribbean groups having rates up to 6 times higher than White British
15
Lifetime morbid risk for schizophrenia is approximately 1%, consistent across cultures per a 2012 international meta-analysis
16
In Japan, the standardized prevalence ratio for schizophrenia is 7.1 per 1,000, with regional variations up to 10.2 in urban Tokyo
17
Among US veterans, schizophrenia prevalence is 1.2%, over twice the general population rate, from VA health records
18
Global DALYs due to schizophrenia were 19.8 million in 2019, ranking it 77th among causes of burden, per GBD study
19
In India, community prevalence of schizophrenia is 3 per 1,000, with treatment gap over 80%, per NIMHANS surveys
20
Female schizophrenia patients outnumber males post-40 years, reversing earlier male predominance, per longitudinal studies
Interpretation
Prevalence And Epidemiology Interpretation
Across prevalence and epidemiology, schizophrenia affects about 24 million people worldwide, translating to roughly 0.32% of the population and an incidence of 15.2 per 100,000 each year, with higher rates in urban areas and a male incidence about 1.4 times that of females.
03 · Category
Prognosis And Outcomes21 stats
01
20-30% of first-episode patients achieve full recovery within 5 years without relapse, per long-term studies
02
Suicide rate in schizophrenia is 5%, 20 times general population, 80% attempt lifetime
03
50% of patients experience significant disability, with 10-15% requiring lifelong institutionalization
04
Life expectancy reduced by 15-20 years due to somatic comorbidity and suicide, meta-analysis 26 studies
05
Relapse rate 78% within 5 years post-first episode without maintenance therapy
06
Negative symptoms remit in only 25% long-term, predicting 60% poor social outcomes
07
40% achieve vocational recovery (stable employment >2 years) with IPS support
08
Cognitive remediation improves cognition 0.45 SD, functioning 0.42 SD at 1 year, meta 40 RCTs
09
Homelessness affects 25-30% of schizophrenia patients over lifetime in US cities
10
Cardiovascular mortality 3.2-fold higher, smoking and meds contribute 50%
11
Marriage rate 20% in schizophrenia vs 80% general population, gender disparity males 10% females 30%
12
Clozapine reduces suicide 75% in high-risk patients, 5-year Finnish registry
13
67% of early-onset cases (<18) have poorer premorbid adjustment and outcomes
14
Functional remission (personal, social, work) in 15-20% after 10 years, OPUS trial
15
Substance use comorbidity worsens prognosis, relapse OR 3.5, recovery halved
16
Women have 20-25% better functional outcomes than men, later onset protective
17
Treatment adherence <50% predicts rehospitalization in 70% within 1 year
18
10-year mortality standardized ratio 2.6, half from natural causes, Danish study 7M
19
Social cognition training improves theory of mind 0.63 SD, real-world skills 0.34 SD
20
30% develop tardive dyskinesia after 5 years antipsychotics, risk higher first-gen 25% vs 13% second-gen
21
Recovery rates higher in developing countries 40% vs 20% developed, WHO IPSS
Interpretation
Prognosis And Outcomes Interpretation
From a Prognosis And Outcomes perspective, even with treatment the long-term picture is often poor with only 20 to 30% of first-episode patients fully recovering without relapse in 5 years while relapse reaches 78% without maintenance therapy, alongside a dramatically higher suicide burden of about 5% and a 15 to 20 year reduction in life expectancy.
More related reading
04 · Category
Symptoms And Clinical Features19 stats
01
Positive symptoms like hallucinations occur in 70-80% of schizophrenia patients at some point, per DSM-5 field trials
02
Auditory hallucinations are reported by 60-90% of schizophrenia patients, most commonly voices commenting or conversing, from meta-analyses
03
Delusions of persecution affect 50-60% of patients, while grandiose delusions occur in 25-30%, per clinical phenomenology studies
04
Negative symptoms such as blunted affect are present in 50% chronically, correlating with poor functioning, from CATIE trial data
05
Cognitive deficits in working memory affect 80-90% of patients, with effect sizes of 1.5-2.0 SD below norms, per CNTRICS initiative
06
40-50% of schizophrenia patients experience command hallucinations, increasing suicide risk 2-3 fold, per voice-hearing studies
07
Formal thought disorder, like derailment, is observed in 60% during acute phases, dropping to 30% in remission
08
Catatonia occurs in 10-15% of schizophrenia cases, with subtypes like stupor in 5%, per DSM-5 prevalence data
09
Visual hallucinations are less common at 27%, versus 74% auditory in first-episode psychosis, from AESOP study
10
Avolition, a key negative symptom, impairs daily functioning in 45% of outpatients, per PANSS subscale scores
11
Disorganized speech patterns persist in 20-30% long-term, linked to frontal lobe dysfunction
12
Olfactory hallucinations occur in 12-20% of patients, often with persecutory content, per sensory studies
13
Emotional flattening is rated moderate-severe in 35% using SANS scale in stable patients
14
25% of patients exhibit somatic delusions, like bodily infestation, more in chronic cases
15
Processing speed deficits average 1.6 SD below controls in 75% of schizophrenia cohorts
16
Poverty of speech (alogia) affects 40% in outpatient settings, predicting relapse
17
Tactile hallucinations reported in 15% , often as formication in drug-naive patients
18
Inappropriate affect seen in 20% during prodromal phases, per ultra-high risk studies
19
Anhedonia prevalence is 60% in schizophrenia, split 40% consummatory and 55% anticipatory
Interpretation
Symptoms And Clinical Features Interpretation
In schizophrenia, positive and negative symptoms often overlap in prevalence, with hallucinations showing up in about 70 to 80 percent and auditory voices in 60 to 90 percent, while negative symptoms like blunted affect appear in roughly 50 percent, reinforcing that the symptoms and clinical features are both common and clinically diverse rather than isolated.
05 · Category
Treatment And Interventions20 stats
01
65% of schizophrenia patients respond to antipsychotics within 6 weeks, but 30% are treatment-resistant, per CATIE trial phase 1
02
Clozapine achieves 30-50% response in treatment-resistant cases versus 4% placebo, CATIE phase 2
03
Cognitive behavioral therapy for psychosis (CBTp) reduces delusions by 15-20% on PANSS, meta-analysis 34 RCTs
04
Long-acting injectable antipsychotics reduce relapse by 20-30% over oral, 2-year RCTs
05
Electroconvulsive therapy (ECT) remission rate 80% in catatonic schizophrenia, open trials
06
Family psychoeducation lowers relapse 50% over 2 years, per 1990s RCTs meta-analysis
07
Sodium valproate augmentation response 45% in clozapine non-responders, small RCTs
08
rTMS to left TPJ reduces auditory hallucinations by 25% severity, meta-analysis 17 studies
09
Supported employment achieves 60% competitive work retention at 18 months vs 20% usual services, IPS model
10
Omega-3 fatty acids adjunct reduce progression 22.6% in UHR, Vienna trial 81 patients
11
Antidepressants like mirtazapine improve negative symptoms 20-30% PANSS, meta-analysis
12
Social skills training improves functioning scores 0.4 SD, but not symptoms, 22 RCTs
13
Paliperidone palmitate LAI relapse rate 13% vs 26% oral at 18 months, PRIDE study
14
Mindfulness-based interventions reduce distress from voices 30%, 8 RCTs meta-analysis
15
Topiramate adjunct decreases weight gain by 2.4kg over clozapine alone, RCTs
16
Assertive community treatment (ACT) reduces hospitalization 50% in high utilizers, 10-year meta
17
Lumateperone 42mg daily superior to placebo PANSS total -22.6 vs -11.9, phase 3 trial
18
Narrative enhancement therapy improves self-stigma 25%, RCT 143 patients
19
Metformin prevents antipsychotic weight gain 3.2kg less at 12 weeks, meta-analysis
20
tDCS to DLPFC improves working memory 20% in 10 sessions, meta-analysis
Interpretation
Treatment And Interventions Interpretation
Overall, the Treatment and Interventions data show that timely and targeted approaches can meaningfully change outcomes, such as 65% responding to antipsychotics within 6 weeks while clozapine improves treatment resistant cases to a 30 to 50% response compared with 4% on placebo and long acting injections cut relapse by 20 to 30% over oral treatment.
report visual · Comparison
Schizo Statistics statistics snapshot
Selected headline statistics from verified sources for a stable visual baseline.
Prenatal famine exposure increases risk 1.7-fold, as in Dutch Hunger Winter cohort of 400,000400,000
Advanced paternal age (>45) raises risk 3.8-fold due to de novo mutations, meta-analysis of 5M births45
Genetic risk variants explain 24% of schizophrenia liability, with polygenic scores predicting 7% variance, per PGC GWAS24%
Family risk: first-degree relatives have 10% risk versus 1% general population, heritability 80%, twin studies10%
Childhood trauma (physical abuse) OR 2.78 for psychosis, dose-response in 38 studies meta-analysis2.78
Cannabis use disorder doubles schizophrenia risk, odds ratio 2.09, dose-dependent per Copenhagen study2.09
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Schizo Statistics. Gitnux. https://gitnux.org/schizo-statistics
MLA
Ryan Townsend. "Schizo Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/schizo-statistics.
Chicago
Ryan Townsend. 2026. "Schizo Statistics." Gitnux. https://gitnux.org/schizo-statistics.
Sources & references
8 datasets cited across this report · attribution is report-level